RT Journal Article
SR Electronic
T1 Allopurinol and Blood Pressure Variability Following Ischemic Stroke and Transient Ischemic Attack: A Secondary Analysis of XILO-FIST
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.06.29.23292066
DO 10.1101/2023.06.29.23292066
A1 MacDonald, Alexander Stuart
A1 Robertson, Michele
A1 Dickie, David Alexander
A1 Bath, Phillip
A1 Forbes, Kirsten
A1 Quinn, Terence
A1 Broomfield, Niall M
A1 Dani, Krishna
A1 Doney, Alex
A1 Muir, Keith W
A1 Struthers, Allan
A1 Walters, Matthew
A1 Barber, Mark
A1 Bhalla, Ajay
A1 Cameron, Alan
A1 Dyker, Alexander
A1 Guyler, Paul
A1 Hassan, Ahamad
A1 Kearney, Mark
A1 Keegan, Breffni
A1 Sekaran, Lakshmanan
A1 Macleod, Mary Joan
A1 Randall, Marc
A1 Shaw, Louise
A1 Subramanian, Ganesh
A1 Werring, David
A1 McConnachie, Alex
A1 Dawson, Jesse
YR 2023
UL http://medrxiv.org/content/early/2023/06/30/2023.06.29.23292066.abstract
AB Background Blood Pressure Variability (BPV) is associated with cardiovascular risk and serum uric acid level. We investigated whether BPV is lowered by allopurinol and whether it is related to markers of cerebral small vessel disease.Methods We used data from a randomised, double-blind, placebo-controlled trial of two years allopurinol treatment after recent ischemic stroke or transient ischaemic attack. Visit-to-visit BPV was assessed using brachial blood pressure (BP) recordings. Short-term BPV was assessed using ambulatory BP monitoring (ABPM) performed at 4 weeks and 2 years. Brain MRI was performed at baseline and 2 years. BPV measures were compared between the allopurinol and placebo groups and with white matter hyperintensity progression.Results 409 participants were included (205 allopurinol; 204 placebo) were included in analyses of visit-to-visit BPV and there were no significant differences between groups. 196 participants were included in analyses of short-term BPV at week 4. Two measures were reduced by allopurinol: the standard deviation (SD) of systolic BP (by 1.30mmHg (95% confidence interval (CI) 0.18–2.42, p=0.023)); and the average real variability (ARV) of systolic BP (by 1.31mmHg (95% CI 0.31–2.32, p=0.011)). There were no differences in other measures at week 4 or in any measure at 2 years.Conclusions Allopurinol treatment did not affect visit-to-visit BPV in people with recent ischemic stroke or TIA. Two BPV measures were reduced at week 4 by allopurinol but not at 2 years. Allopurinol is unlikely to lead to an important reduction in BPV in people with ischemic stroke or TIA.Competing Interest StatementAS holds a patent for the use of xanthine oxidase inhibition for the treatment of angina pectoris. DD received payment for image analysis in this study. The other authors declare they have no competing interests.Clinical TrialClinicalTrials.gov NCT02122718Clinical Protocols https://pubmed.ncbi.nlm.nih.gov/30246149/ Funding StatementXILO-FIST was financially supported by a joint Stroke Association and British Heart Foundation Programme Grant (ref: TSA BHF 2013/01).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:XILO-FIST was approved by the UK MHRA and NHS Research Ethics Committee (REC number 14/WS/0113)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe datasets analysed that support the findings of the present study are available from the corresponding author upon reasonable request.ABPMAmbulatory blood pressure monitoringARVAverage real variabilityBMIBody mass indexBPBlood pressureBPVBlood pressure variabilityCIConfidence intervalCVCoefficient of variationDBPDiastolic blood pressureIQRInterquartile RangeMoCAMontreal cognitive assessmentMRIMagnetic resonance imagingNIHSSNational institute of health stroke scaleSBPSystolic blood pressureSDStandard deviationTIATransient ischemic attackVIMVariation independent of the meanWMHWhite matter hyperintensityXILO-FISTXanthine oxidase inhibition for the improvement of long-term outcomes following ischemic stroke and transient ischemic attack